Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Journal of Clinical Microbiology
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About JCM
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Virology

Prevalence and Management of Invalid GeneXpert Enterovirus Results Obtained with Cerebrospinal Fluid Samples: a 2-Year Study

Susan E. Sefers, Anna K. Raymer, Jessica T. Kilby, David H. Persing, Yi-Wei Tang
Susan E. Sefers
1Departments of Pathology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna K. Raymer
1Departments of Pathology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica T. Kilby
1Departments of Pathology
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David H. Persing
3Cepheid, Sunnyvale, California
4Department of Pathology, Stanford University School of Medicine, Palo Alto, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yi-Wei Tang
1Departments of Pathology
2Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: yiwei.tang@vanderbilt.edu
DOI: 10.1128/JCM.01238-09
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

A total of 525 cerebrospinal fluid (CSF) samples submitted during the 2007 and 2008 enteroviral seasons were included in a study to determine the prevalence of and potential risk factors for invalid Cepheid GeneXpert enterovirus assay (GXEA) results, as well as possible solutions for the problem. The invalid GXEA results were reported for 43 (8.2%) specimens and correlated with increased visibility of red blood cells (P < 0.0001) but not with CSF xanthochromia and clotting. Invalid GXEA result rates were markedly diminished by 82.1% and 96.0% and test sensitivities were minimally decreased by 1.7% and 3.6% when these specimens were tested at a 1:5 dilution and after a freeze-thaw cycle, respectively.

Enterovirus (EnV) meningitis can be difficult to distinguish from disease caused by other etiologic agents when patients present with nonspecific pathogenic symptoms and signs, such as fever, headache and stiff neck, and pleocytosis in cerebrospinal fluid (CSF) (4, 8, 9). Nucleic acid amplification-based procedures for the detection of EnV RNA in CSF have replaced cell culture as the test of choice (10, 11, 14). The GeneXpert enterovirus assay (GXEA; Cepheid, Sunnyvale, CA) is designed as an integrated system combining specimen processing, EnV amplification, and detection in a disposable cartridge which takes 2.5 h to detect EnV from CSF (6, 7, 12). It is designed for on-demand testing, such that “stat” PCR results can be returned to the emergency room physicians in time for patient management decisions to be made in real time. The system includes an internal control that provides a means to detect amplification inhibitors. When the internal control does not amplify, the presence of an amplification inhibitor is assumed and the result is reported as “invalid.” Invalid results, if and when they occur, could delay patient management in the emergency setting.

We performed a 2-year prospective study to determine the prevalence of invalid GXEA results and explore the potential risk factors related to the occurrence of invalid results. We also validated two alternative procedures to minimize the occurrence of these invalid results for EnV detection in CSF.

(This study was presented in part at the 25th Annual Meeting of the Pan American Society for Clinical Virology, Daytona Beach, FL, 19 to 22 April, 2009.)

Clinical samples.

CSF specimens submitted to Vanderbilt University Medical Center between 1 April 2007 and 20 September 2008 for detection of EnV by PCR were collected consecutively. Specimens with enough leftover volume and still unfrozen after the completion of diagnostic testing were included in the study.

Determination of CSF characteristics.

Each CSF sample was visually examined for visible red blood cells (RBCs), clotting, and the presence of xanthochromia. RBC visibility was graded semiquantatively on a scale using rankings of clear, 1+, 2+, 3+, and 4+. These grades were based on specimen colors and turbidities which roughly correspond to CSF RBC counts of <200/μl (clear), 200 to 5,000/μl (1+), 5,000 to 75,000/μl (2+), 75,000 to 150,000/μl (3+), and >150,000/μl (4+).

GXEA.

The GXEA kit was purchased from Cepheid (Sunnyvale, CA). The information from each kit lot was recorded. CSF samples were tested using the GXEA as previously described (6, 7). In brief, 140 μl of CSF was added to the GeneXpert cartridge and then processed automatically for the different steps of sample preparation and amplification. After the diagnostic procedure was completed, the following two additional procedures were performed within 48 h on unfrozen CSF specimens with enough leftover volume prior to the routine GXEA procedure: (i) a 1:5 dilution, in which a CSF specimen was diluted once with saline in a 1:5 ratio; and/or (ii) a freeze-thaw cycle, in which a CSF specimen was quickly frozen in dry ice and thawed in a 37°C water bath one time.

During the study period, a total of 525 CSF specimens were submitted to the diagnostic laboratories. The samples spanned two EnV seasons, with 301 collected in 2007 and 224 collected in 2008. The patients' ages ranged from less than 1 day old to 74 years old, with an average age of 8 years. The ratio of males to females was 0.56:0.44. Among the 525 CSF samples enrolled in this study, 95 were positive for EnV by the GXEA, giving a positive rate of 18.1%. Invalid GXEA results were reported for 43 (8.2%) specimens during the 2-year study period. The invalid-result rate was 9.6% in 2007 and 6.3% in 2008, with no significant change in the invalid-result rate from 2007 to 2008 (χ2 = 1.96, P > 0.05). Included in the evaluation were GXEA kits with seven different lot numbers purchased during the 2-year study period, and invalid results were evenly distributed among the seven lots.

Assuming that the built-in internal control was functioning correctly to detect inhibitory or interfering substances, we next assessed potential factors associated with the occurrence of invalid results. Invalid results correlated with visible RBCs in the CSF specimens tested (Table 1). Of the 525 CSF samples tested, 388 samples were graded as clear, of which only 19 (4.9%) samples gave invalid results. The invalid-result rate but not the EnV-positive rate correlated with RBC cellularity (χ2 trend = 38.01, P < 0.0001). In comparison to the results for clear specimens, CSF specimens with 1+, 2+, 3+, and 4+ RBC cellularity gave odds ratios at a 1.07-, 2.92-, 6.28-, and 8.60-fold likelihood, respectively, of encountering invalid results (Table 1). Visible RBC clots were only seen in six samples and were not related to the occurrence of invalid results (data not shown). Xanthochromia was noted in 44 CSF specimens of which 2 (4.5%) tested invalid; however, no statistical significance was discovered (χ2 = 0.85, P > 0.05) in comparison to the 41 (8.5%) invalid findings in the 481 nonxanthochromic samples. These data indicated that invalid GXEA results were correlated with increased RBC cellularities of the CSF specimens tested.

View this table:
  • View inline
  • View popup
TABLE 1.

Invalid GXEA results correlate to levels of visible RBCs in CSF specimens

CSF specimens with sufficient volume that were still unfrozen were retested to pursue potential solutions for minimizing the occurrence of invalid results. Twenty-eight CSF specimens were tested again after a 1:5 dilution. All but five diluted samples gave valid results, thus diminishing the invalid-result rate by 82.1% (Table 2). Twenty-five samples were subjected to a one-time freeze-thaw cycle before retesting, as reported recently (12), and all invalid results were resolved except for one sample, reducing the invalid-result rate by 96.0%. Taken together, we found that a one-time freeze-thaw cycle or a 1:5 dilution of the tested specimen markedly diminished the invalid-result rate, with no statistical difference indicated between the results for the two procedures (Fisher's exact test, P > 0.05).

View this table:
  • View inline
  • View popup
TABLE 2.

A 1:5 dilution of fresh specimens or a one-time freeze-thaw of specimens diminishes invalid results without decreasing test sensitivity

We next studied whether the two procedures influenced diagnostic sensitivities. Among all positive specimens with enough leftover volume, retesting after a 1:5 dilution and a one-time freeze-thaw cycle achieved sensitivities of 98.3% and 96.4%, respectively (Table 2). There was no statistical difference in sensitivity between the two procedures (Fisher's exact test, P > 0.05). In addition, there were three and four specimens with originally invalid results that became positive after the dilution and the freeze-thaw cycle, respectively. Together, these data indicated that using a 1:5 dilution or one-time freeze-thaw cycle on CSF specimens with RBC cellularity remarkably diminished invalid test results without significantly decreasing the test's sensitivity.

This study presents our 2-year data on EnV detection by the Cepheid GXEA. Invalid results occurred at a rate of 8.2% when original, untreated CSF specimens were used. These results were in the range of the results of other published studies, which have ranged from 6.7% to 16% (7, 12), and show that the internal control is functioning correctly to detect inhibition. We found that invalid results were highly correlated to the level of RBC cellularity, i.e., “bloody tap.” Importantly, we also found that one of two simple procedures carried out prior to testing, a 1:5 dilution or a one-time freeze-thaw cycle, remarkably diminished the frequency of invalid results without significantly decreasing the test's diagnostic sensitivity. This information may be useful for laboratories performing on-demand testing for EnVs in CSF, especially for those supporting emergency room management of meningitis cases. One limitation of this study is that the results from the GXEA were not compared with a reference method; therefore, the possibility of false-negative results, as previously indicated (12), was not addressed. However, a review of our data on negative specimens failed to show the “low positive but below cutoff” results reported by Seme et al. in any of our reported negative specimens with valid internal control results. Thus, in our experience, a false-negative result due to partial inhibition that is undetected by the internal control seems unlikely, but it is intriguing that Seme et al. showed a potential benefit in incorporating a freeze-thaw step to address this issue in their laboratory (12).

Bloody taps are not uncommon in the evaluation of pediatric or adult meningitis, so rendering these specimens evaluable would potentially be useful, especially if results need to be returned quickly. The Cepheid product insert claims that there is no inhibition in CSF samples with RBCs up to 2.5% blood (vol/vol). In our study, when 3+ or higher (>75,000/μl) RBC cellularities in CSF specimens were visualized, the invalid GXEA results increased significantly, with an odds ratio over 3. There are several potential explanations for the RBC cellularity-related invalid results. First, components of RBCs are known to inhibit in vitro nucleic acid amplification. Heme is a well-known amplification inhibitor (1, 2, 15). In our study, however, a freeze-thaw cycle prior to testing significantly diminished invalid-result frequencies. Since heme is present in these samples, it is difficult to determine whether heme played a significant role as an inhibitor in the GXEA test system. It has been reported that several commonly used one-step RNA-targeted enzymes, such as rTth, are usually not affected by heme (3).

A second explanation could be that the high level of RBCs in CSF affects the lysis of cells and virions, resulting in incomplete release of viral nucleic acids. This could be manipulated by adjustment of the volume of the CSF specimen. The additional dilution or freeze-thaw cycle can improve cell and virion lysis and viral nucleic acid release, thereby diminishing invalid-result frequencies (12). The last explanation is that, in the GXEA test cycle, the sample is pumped from one chamber to another within the microfluidic device. High levels of RBCs, with or without clot formation, could block the movement of liquids between test chambers. Both of the two explanations are supported by the fact that either a 1:5 dilution or a one-time freeze-thaw cycle remarkably diminishes the frequency of invalid results.

There have been numerous studies of specimen treatments or added reagents that act as amplification facilitators and also of possible solutions for amplification inhibitors (1, 3, 5, 13). Adding additional chemicals or steps to the lysis procedure of the GXEA could potentially enhance cell and virus lysis, thereby diminishing invalid results, but would constitute “off-label” use and require validation as performed here. In our routine diagnostic services, any CSF specimens with visible RBCs are automatically diluted to 1:5 prior to testing to keep the test turnaround time rapid without significantly decreasing test sensitivity.

ACKNOWLEDGMENTS

We thank Melinda McCormac, Sharon Smith, Mary Beth Underwood, Rebekah Glisson, Jennifer Smith, Shufang Meng, Criziel Quinn, and Haijing Li for their assistance with the collection and processing of clinical specimens.

This study was financially supported in part by an unrestricted educational grant from Cepheid.

FOOTNOTES

    • Received 24 June 2009.
    • Accepted 6 July 2009.
  • Copyright © 2009 American Society for Microbiology

REFERENCES

  1. 1.↵
    Abu Al-Soud, W., and P. Radstrom. 2000. Effects of amplification facilitators on diagnostic PCR in the presence of blood, feces, and meat. J. Clin. Microbiol.38:4463-4470.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Akane, A., K. Matsubara, H. Nakamura, S. Takahashi, and K. Kimura. 1994. Identification of the heme compound copurified with deoxyribonucleic acid (DNA) from bloodstains, a major inhibitor of polymerase chain reaction (PCR) amplification. J. Forensic Sci.39:362-372.
    OpenUrlPubMedWeb of Science
  3. 3.↵
    Al-Soud, W. A., and P. Radstrom. 2001. Purification and characterization of PCR-inhibitory components in blood cells. J. Clin. Microbiol.39:485-493.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    Archimbaud, C., M. Chambon, J. L. Bailly, I. Petit, C. Henquell, A. Mirand, B. Aublet-Cuvelier, S. Ughetto, J. Beytout, P. Clavelou, A. Labbe, P. Philippe, J. Schmidt, C. Regagnon, O. Traore, and H. Peigue-Lafeuille. 2009. Impact of rapid enterovirus molecular diagnosis on the management of infants, children, and adults with aseptic meningitis. J. Med. Virol.81:42-48.
    OpenUrlCrossRefPubMed
  5. 5.↵
    Boddinghaus, B., T. A. Wichelhaus, V. Brade, and T. Bittner. 2001. Removal of PCR inhibitors by silica membranes: evaluating the Amplicor Mycobacterium tuberculosis kit. J. Clin. Microbiol.39:3750-3752.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    Kost, C. B., B. Rogers, M. S. Oberste, C. Robinson, B. L. Eaves, K. Leos, S. Danielson, M. Satya, F. Weir, and F. S. Nolte. 2007. Multicenter beta trial of the GeneXpert enterovirus assay. J. Clin. Microbiol.45:1081-1086.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Marlowe, E. M., S. M. Novak, J. J. Dunn, A. Smith, J. Cumpio, E. Makalintal, D. Barnes, and R. J. Burchette. 2008. Performance of the GeneXpert enterovirus assay for detection of enteroviral RNA in cerebrospinal fluid. J. Clin. Virol.43:110-113.
    OpenUrlCrossRefPubMed
  8. 8.↵
    Mulford, W. S., R. S. Buller, M. Q. Arens, and G. A. Storch. 2004. Correlation of cerebrospinal fluid (CSF) cell counts and elevated CSF protein levels with enterovirus reverse transcription-PCR results in pediatric and adult patients. J. Clin. Microbiol.42:4199-4203.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    Ramers, C., G. Billman, M. Hartin, S. Ho, and M. H. Sawyer. 2000. Impact of a diagnostic cerebrospinal fluid enterovirus polymerase chain reaction test on patient management. JAMA283:2680-2685.
    OpenUrlCrossRefPubMedWeb of Science
  10. 10.↵
    Rotbart, H. A., J. P. Kinsella, and R. L. Wasserman. 1990. Persistent enterovirus infection in culture-negative meningoencephalitis: demonstration by enzymatic RNA amplification. J. Infect. Dis.161:787-791.
    OpenUrlCrossRefPubMedWeb of Science
  11. 11.↵
    Schlesinger, Y., M. H. Sawyer, and G. A. Storch. 1994. Enteroviral meningitis in infancy: potential role for polymerase chain reaction in patient management. Pediatrics94:157-162.
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    Seme, K., T. Mocilnik, K. F. Komlos, A. Doplihar, D. H. Persing, and M. Poljak. 2008. GeneXpert enterovirus assay: one-year experience in a routine laboratory setting and evaluation on three proficiency panels. J. Clin. Microbiol.46:1510-1513.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    Shafer, R. W., D. J. Levee, M. A. Winters, K. L. Richmond, D. Huang, and T. C. Merigan. 1997. Comparison of QIAamp HCV kit spin columns, silica beads, and phenol-chloroform for recovering human immunodeficiency virus type 1 RNA from plasma. J. Clin. Microbiol.35:520-522.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    Smalling, T. W., S. E. Sefers, H. Li, and Y. W. Tang. 2002. Molecular approaches to detecting herpes simplex virus and enteroviruses in the central nervous system. J. Clin. Microbiol.40:2317-2322.
    OpenUrlFREE Full Text
  15. 15.↵
    Staudinger, R., N. G. Abraham, R. D. Levere, and A. Kappas. 1996. Inhibition of human immunodeficiency virus-1 reverse transcriptase by heme and synthetic heme analogs. Proc. Assoc. Am. Physicians108:47-54.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
Prevalence and Management of Invalid GeneXpert Enterovirus Results Obtained with Cerebrospinal Fluid Samples: a 2-Year Study
Susan E. Sefers, Anna K. Raymer, Jessica T. Kilby, David H. Persing, Yi-Wei Tang
Journal of Clinical Microbiology Aug 2009, 47 (9) 3008-3010; DOI: 10.1128/JCM.01238-09

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Journal of Clinical Microbiology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence and Management of Invalid GeneXpert Enterovirus Results Obtained with Cerebrospinal Fluid Samples: a 2-Year Study
(Your Name) has forwarded a page to you from Journal of Clinical Microbiology
(Your Name) thought you would be interested in this article in Journal of Clinical Microbiology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Prevalence and Management of Invalid GeneXpert Enterovirus Results Obtained with Cerebrospinal Fluid Samples: a 2-Year Study
Susan E. Sefers, Anna K. Raymer, Jessica T. Kilby, David H. Persing, Yi-Wei Tang
Journal of Clinical Microbiology Aug 2009, 47 (9) 3008-3010; DOI: 10.1128/JCM.01238-09
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • Clinical samples.
    • Determination of CSF characteristics.
    • GXEA.
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

cerebrospinal fluid
Diagnostic Errors
Enterovirus Infections
Molecular Diagnostic Techniques
Reagent Kits, Diagnostic

Related Articles

Cited By...

About

  • About JCM
  • Editor in Chief
  • Board of Editors
  • Editor Conflicts of Interest
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Resources for Clinical Microbiologists
  • Ethics
  • Contact Us

Follow #JClinMicro

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

 

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0095-1137; Online ISSN: 1098-660X